Are aggressive pituitary tumors and carcinomas two sides of the same coin? Pathologists reply to clinician’s questions
Jacqueline Trouillas, Chiara Villa(Centre National de la Recherche Scientifique), Vera Popović(University of Belgrade), Alexandre Vasiljevic(Centre de Recherche en Neurosciences de Lyon), Anne Wierinckx(Lyon 1 Université), Gérald Raverot(Université Claude Bernard Lyon 1), Olaf M. Dekkers(Leiden University), Marie‐Lise Jaffrain‐Rea(Inserm), Stephan Petersenn(Endocyte (United States)), Ann McCormack(Garvan Institute of Medical Research), Pia Burman(Malmö University)
Cited by 62
Related Papers
Intertumoral Heterogeneity within Medulloblastoma Subgroups
|Cancer Cell|2017|1.3k
Heart rate variability and first cardiovascular event in populations without known cardiovascular disease: meta-analysis and dose–response meta-regression
|EP Europace|2013|509
Clinical Characteristics and Therapeutic Responses in Patients with Germ-Line<i>AIP</i>Mutations and Pituitary Adenomas: An International Collaborative Study
|The Journal of Clinical Endocrinology & Metabolism|2010|374
Prognostic value of medulloblastoma extent of resection after accounting for molecular subgroup: a retrospective integrated clinical and molecular analysis
|The Lancet Oncology|2016|374
A Consensus on the Diagnosis and Treatment of Acromegaly Comorbidities: An Update
|The Journal of Clinical Endocrinology & Metabolism|2019|363